Press release
Emerging Drivers Influencing The Growth Of The Chronic Liver Diseases Therapeutics Market: Market Growth Driven By Increased Alcohol Use And Liver Health Challenges
Chronic Liver Diseases Therapeutics Market Analysis
How Big Is the Chronic Liver Diseases Therapeutics Market Size Expected to Be by 2034?
The market size for therapeutics of chronic liver disease has seen a swift expansion in the recent past. The market is projected to escalate from $14.38 billion in 2024 to nearly $15.92 billion in 2025, fueled by a compound annual growth rate (CAGR) of 10.7%. Factors such as an increased prevalence of viral hepatitis, rising obesity rates, an aging population, heightened awareness surrounding liver health, and improved access to treatment can be credited to the historical period growth.
In the upcoming years, the therapeutics market for chronic liver disease is anticipated to experience a swift expansion. The market is projected to reach $23.83 billion by 2029, with a compound annual growth rate (CAGR) of 10.6%. The expected surge can be attributed to the amplified emphasis on personalized medicine, growth in the stream of innovative therapies, extension of telemedicine, digital health solutions, and an increase in demand for liver disease prevention methods. Additionally, the escalating incidents of viral hepatitis also contribute to this growth. Key trends encompass the assimilation of artificial intelligence in diagnostics, the use of biologics and gene therapies, non-invasive treatment alternatives, combined therapies, and advancements in patient-centric care models.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21145
What Are the Emerging Segments Within the Chronic Liver Diseases Therapeutics Market?
The chronic liver diseases therapeutics market covered in this report is segmented -
1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy
2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders
3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals
2) By Immunosuppressants: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors
3) By Vaccines: Hepatitis A Vaccine, Hepatitis B Vaccine, Combination Hepatitis Vaccines
4) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin
5) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone
6) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies
7) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21145&type=smp
What Long-Term Drivers Are Shaping Chronic Liver Diseases Therapeutics Market Trends?
An uptick in alcohol intake is predicted to drive the expansion of the market for chronic liver disease therapies. The practice of consuming alcoholic beverages, which holds the potential for a range of health consequences due to its ethanol content, is growing more common due to factors like societal acceptance, increased incomes and broadened availability on a global scale. Therapies for chronic liver disease serve to limit the damage to the liver caused by excessive drinking, aiding in the deceleration of the progression of the disease and the enhancement of liver function. As an example, a 1.2% rise in direct-to-consumer wine case sales in 2023 relative to 2022 was noted by First Citizens Bank, a U.S. banking institution, in June 2024. Additionally, a report released by Kirin Holdings Company Limited, a Japan-based beverage company, in December 2023 stated that approximately 192.1 million kiloliters of beer were consumed in 2022, showing a 2.9% growth from the year before. As such, the escalating consumption of alcohol is boosting the chronic liver disease therapeutics market's growth.
Who Are the Top Competitors in Key Chronic Liver Diseases Therapeutics Market Segments?
Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy's Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.
What Are the Major Trends Shaping the Chronic Liver Diseases Therapeutics Market?
Leading firms in the therapeutics market for chronic liver diseases are concentrating on the creation of novel inventions such as RNA therapies. These therapies are designed to target the underlying genetic and molecular mechanisms, providing efficient and personalized treatment options. RNA therapies are an advanced form of medical treatment that employs RNA molecules to control gene expression or protein production. The goal is to prevent or treat diseases by targeting specific genetic mechanisms. For example, in May 2022, the UK-based biotech company, Ochre Bio, unveiled its cutting-edge 'Liver ICU' research facility at BioLabs@NYULangone, a biopharma incubator in New York City. They assess the efficacy of next-gen RNA therapeutics by using whole human livers maintained on perfusion machines at this high-tech site. By utilizing discarded donor livers for investigation, the facility intends to hasten the drug development process and improve the accuracy of liver treatment studies by duplicating human physiological conditions.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/chronic-liver-diseases-therapeutics-global-market-report
Which Regions Are Becoming Hubs for Chronic Liver Diseases Therapeutics Market Innovation?
North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Chronic Liver Diseases Therapeutics Market?
2. What is the CAGR expected in the Chronic Liver Diseases Therapeutics Market?
3. What Are the Key Innovations Transforming the Chronic Liver Diseases Therapeutics Industry?
4. Which Region Is Leading the Chronic Liver Diseases Therapeutics Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Emerging Drivers Influencing The Growth Of The Chronic Liver Diseases Therapeutics Market: Market Growth Driven By Increased Alcohol Use And Liver Health Challenges here
News-ID: 4069926 • Views: …
More Releases from The Business Research Company
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Company Registration Service Market Through 2025?
The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth…
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025?
In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of…
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025?
The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in…
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025?
In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
